Global population-based prevalence of genetic carriers of CDH1-associated hereditary diffuse gastric cancer
In brief
Predicted variants raise estimated CDH1 carrier frequency to 44 per 100,000
In a genomic database of 807,162 people, curated disease-causing CDH1 variants corresponded to an estimated 8.67 carriers per 100,000; adding rare variants predicted damaging by computer methods raised the estimate to 44.1. The expanded estimate was highest in the Middle Eastern ancestry group, but those additional variants need clinical and functional validation before their disease risk is clear.
- Journal
- Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Q1)
- Published
- 9 November 2026
- Study design
- Cross-sectional study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Vitchapong Prasitsumrit, Nich Paibulsirijit, Nipith Charoenngam
- PMID
- 43002353
- DOI
- 10.1007/s10120-026-01823-x
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 15 November 2026): CDH1 carrier prevalence informs hereditary cancer screening
Abstract
BACKGROUND: Hereditary diffuse gastric cancer (HDGC) is a rare autosomal dominant genetic disorder caused by loss-of-function mutations in the tumor suppressor gene CDH1. We aimed to estimate the carrier prevalence of HDGC-associated CDH1 variants across genetic ancestry groups using a large genomic database to identify potential disparities. METHODS: We conducted a population-based cross-sectional analysis of 807,162 unrelated individuals in gnomAD v4.1 across diverse genetic ancestry groups. CDH1 variants were identified using two approaches: (1) pathogenic or likely pathogenic (P/LP) variants classified by ClinVar or ClinGen, and (2) additional rare variants predicted to be deleterious in silico, including nonsense, frameshift, deleterious in-frame indels, splice-disrupting, and supported missense variants. Carrier frequency was estimated from combined allele frequencies and stratified by genetic ancestry. RESULT: Among 3,381 CDH1 variants, 137 met study criteria. 47 were classified as P/LP by ClinVar or ClinGen, and 90 additional variants were predicted to be deleterious in silico. Using curated P/LP variants, the overall estimated carrier frequency was 8.67 per 100,000 individuals, with the highest ancestry-specific estimate in non-Finnish Europeans at 10.0 per 100,000. No carriers were observed in Ashkenazi Jewish, Finnish, or Middle Eastern groups. Inclusion of in silico-predicted variants increased the estimated carrier frequency to 44.1 per 100,000, with the highest estimate in the Middle Eastern group at 165.0 per 100,000. CONCLUSION: HDGC-associated CDH1 variants may be more broadly distributed across populations than previously recognized. This genotype-first approach provides population-level carrier estimates independent of clinical ascertainment and highlights ancestry-related variation requiring further clinical and functional validation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.